Evolus Inc
NASDAQ:EOLS
Evolus Inc
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 167 full-time employees. The company went IPO on 2018-02-08. The Company’s first commercial product is Jeuveau, which is an approximately 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company offers customers and consumers a compelling value proposition with Jeuveau. BOTOX (onabotulinumtoxinA) is also an approximately 900 kDa botulinum toxin type A complex approved in the United States.
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 167 full-time employees. The company went IPO on 2018-02-08. The Company’s first commercial product is Jeuveau, which is an approximately 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company offers customers and consumers a compelling value proposition with Jeuveau. BOTOX (onabotulinumtoxinA) is also an approximately 900 kDa botulinum toxin type A complex approved in the United States.
Revenue Growth: Evolus reported third quarter revenue of $69 million, up 13% over the prior year, driven by strong Jeuveau demand and early contributions from Evolysse.
Profitability Outlook: The company reaffirmed expectations to achieve profitability in Q4 2025 and sustainable annual profitability beginning in 2026.
Stable Guidance: Full-year 2025 revenue guidance was reiterated at $295–305 million, with Evolysse expected to contribute 10–12% of total revenue.
Expense Management: Operating expenses were successfully reduced, with non-GAAP operating expenses falling to $49.7 million in Q3 from $54 million in Q2.
Product Adoption: Evolysse launch continues to scale, with 4,000 customers trained and $5.7 million in Q3 revenue; adoption is linked to hands-on training.
Market Share: Jeuveau maintained a 14% U.S. market share, outperforming a category that remains down single digits for the year.
Tariff Preparedness: Management is proactively mitigating tariff risks, with current inventory levels expected to last through Q1 2026 and minimal near-term impact.
Portfolio Strategy: Introduction of the first product bundle aims to drive synergies between Jeuveau and Evolysse and capture more account share.
